A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Clinical trial NCT06280391 · COMPLETED
Trial details
- NCT number
- NCT06280391
- Sponsor
- Sanofi
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-20
- Primary completion
- 2025-09-16
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.